PMV Pharmaceuticals, Inc. (PMVP) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

34/ 100

GoAI Score

Sell

Valuation

30

Expensive

Sentiment

62

Bullish

Risk

66

High Risk

Momentum

35

Weakening

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: David H. Mack
Listed since: Sep 25, 2020
Employees: 54

Market position

Day range

Current $1.44

$1.35$1.45

52-week range

Current $1.44

$1.02$1.88

Open: $1.37
Previous close: $1.375
Volume: 673.56K; 1.59× average
Average volume: 424.4K; Average daily volume
Market cap: 76.8M USD
Beta: 1.37; Market reference 1
50-day average: $1.2535; +14.88% above average
200-day average: $1.2674; +13.62% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 28.53M USD
P/E (TTM): -1.01×
P/B (TTM): 1.08×
P/S (TTM): 0×
EV / EBITDA: -0.36×
Earnings yield: -118.37%
Free cash flow yield: -112.07%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -74.24%
Return on assets: -66.70%
Return on invested capital: -79.45%

Financial health

Debt / equity: 0×
Current ratio: 10.09×
Altman Z-score: -5.89
Piotroski F-score: 1 of 9

Financial statements

Income trends

Operating income

−86.21M USD-0.89%

Net income

−77.74M USD-32.42%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	—	1.14M USD	1.26M USD	650K USD	1.28M USD
Gross profit	—	−1.14M USD	−1.26M USD	−650K USD	−1.28M USD
Research and development	69.88M USD	57.38M USD	54.63M USD	51.67M USD	36.19M USD
Selling, general, and administrative	16.33M USD	26.92M USD	24.25M USD	24.72M USD	20.83M USD
Operating expenses	86.21M USD	84.3M USD	78.88M USD	76.39M USD	57.01M USD
Interest income	6.34M USD	10.66M USD	11.17M USD	3.63M USD	449K USD
Depreciation and amortization	133K USD	1.14M USD	1.26M USD	650K USD	1.28M USD
Operating income	−86.21M USD	−85.45M USD	−80.13M USD	−77.04M USD	−58.29M USD
Net income	−77.74M USD	−58.71M USD	−68.96M USD	−73.32M USD	−57.85M USD

Company facts updated Sep 11, 2026.

Earnings

EPS beat rate: 64%; 7 beats, 3 misses, 1 met estimate
Average EPS surprise: +13.83%; 11 comparable reports
Latest EPS result: -0.34; Estimate -0.39 · Beat by 12.26%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$5.00

247.22% upside

Past 12 months12-month forecastHigh $5.00Average $5.00Low $5.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%

Buy4100%

Hold00%

Sell00%

Strong sell00%

Recent analyst actions

2 institutions

OppenheimermaintainOutperformMay 13, 2026

PMVP news

globenewswire.comAug 31, 2026

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule…

Read source

globenewswire.comAug 31, 2026

PMV Pharma Announces Proposed Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule…

Read source

globenewswire.comAug 31, 2026

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule…

Read source

zacks.comAug 19, 2026

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read source

globenewswire.comAug 14, 2026

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule…

Read source

zacks.comJun 24, 2026

PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why

PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read source